5-Amino-1MQ Key Research Facts Chemical name: 5-Amino-1-Methylquinolinium (also abbreviated as 5A-1MQ or 5MQ) Target enzyme: Nicotinamide N-Methyltransferase (NNMT) Mechanism: Competitive inhibition of NNMT reduces 1-MNA production, preserves nicotinamide for NAD+ synthesis and SAM for epigenetic methylation Selectivity: High selectivity for NNMT does not inhibit related SAM-dependent methyltransferases or NAD+ salvage pathway enzymes Membrane permeability: High passive and active transport permeability confirmed in PAMPA and Caco-2 cell assays NNMT expression: Upregulated in obese adipose tissue, multiple cancer types, and aged skeletal muscle tissue contexts of primary research interest Downstream targets: NAD+ availability, SIRT1/SIRT3 activity, SAM-dependent epigenetic methylation, lipogenesis, energy expenditure Pre-clinical models: Diet-induced obese (DIO) mice, 3T3-L1 adipocyte cell models, aged mouse skeletal muscle models, HeLa cancer cell lines In vitro cell viability: No impact on cell viability at 10 M concentration in 3T3-L1 pre-adipocytes in published toxicity profiling What Does 5-Amino-1MQ Do in Research
In simple terms: Capsules: easier, gut-focused, less direct systemic exposure Injections: more direct, stronger systemic exposure, more care required This does not mean one form is always better
To address these challenges, various delivery methods have been investigated, including viral vectors, non-viral vectors, and rational design strategies such as chemical modifications, cationic liposomes, polymers, nanocarriers, and biocoupled siRNAs, aimed at enhancing stability and intracellular delivery (Liu F
If these vaccine-related AEs (e.g., myocarditis, stroke, or thromboembolism) are misclassified as PASC, this would artificially inflate the reported PASC incidence in the vaccinated group
